Housed since 1996 in Bulle, in the heart of Gruyère, UCB has invested approximately CHF 500 million to date in the site, which features advanced industrial equipment at the forefront of innovation and technology.
The biotechnological production unit opened in October 2014 allows UCB to provide treatments to patients suffering from rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial pondylarthrite and Crohn’s disease.
The Bulle site is certified by the environmental standards ( ISO 14001 ) and standards of safety and health at work ( OHSAS 18001 ) and is regularly inspected for quality compliance by various health authorities worldwide, such as Swissmedic , Food & Drug Administration (FDA) and the Japanese authorities (PMDA).
The Swiss site comprises three legal entities:
– UCB SA Farchim
– UCB-Pharma AG (commercial subsidiary to the Swiss market)
– UCB SA Medical Devices
The Bulle site currently has more than 400 members of staff .
Contact
UCB Farchim SA
Zone Industrielle de Planchy d’Avau
Chemin de Croix Blanche , 10
CH – 1630 Bulle
Tel: +00 41 26 919 0200
Fax: +00 41 26 919 0240
UCB Pharma AG
Zone Industrielle de Planchy d’Avau
Chemin de Croix Blanche , 10
CH – 1630 Bulle
Tel: +00 41 26 919 0180
Fax: +00 41 26 919 0181
Contact persons: Catherine Sauteur
Switzerland and South Korea may be separated by thousands of kilometres, but their economic relationship has never been closer. Bilateral trade reached nearly USD 8 billion in 2025, pharmaceutical flows…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
Natural remedies are on the rise. The USD 80 billion global natural health products market is projected to nearly double by 2033, according to Market Growth Reports, as patients with…
Ophthalmology is one of the hottest niches in pharma right now. Investment is flowing in, M&A is up, and a broad cast of actors – from Big Pharma to legacy…
One in six infections worldwide is now resistant to first-line antibiotics, making antimicrobial resistance (AMR) a major global health threat. Despite an extremely challenging commercial landscape, a handful of bold…
Switzerland has become a global leader in cutting-edge cancer research, with close collaborations between research institutions, hospitals, and private industry fostering the next generation of globally impactful cancer innovation. …
As global trade tensions escalate, Switzerland’s export-driven pharmaceutical industry finds itself at a challenging moment. In May 2025, the United States imposed tariffs of up to 39 percent on Swiss…
In an uncertain world, Europe – with Switzerland at its heart – is reclaiming its role as an epicentre for testing, scaling, and integrating new medical technologies. While much…
Manufacturing – long sidelined as a relatively prosaic element of the global pharma supply chain – is back in the news. Investment in manufacturing facilities is skyrocketing as sponsors rush…
Switzerland stands among the world’s leading pharmaceutical manufacturing and export hubs; though that position now faces headwinds from recent US policy moves, as detailed elsewhere in this report. Yet making…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact…
See our Cookie Privacy Policy Here
